Skip to main content
. 2021 Jun 21;10(6):991. doi: 10.3390/antiox10060991

Table 1.

Demographic and clinical characteristics of the patients and the healthy subjects.

Healthy Subjects
n = 50
COVID-19 Negative Patients
n = 45
COVID-19 Positive Patients
n = 126
Demographic variables
Sex, male 38 (76.0) 30 (66.7) 68 (54.8) a
Age, years 75 (66–84) 84 (75–89) b 71 (58–83)
Smoking, n (%) 19 (38.0) 16 (35.6) 6 (4.8) b,d
Alcohol intake, n (%) 28 (56.0) 7 (15.5) b 6 (4.8) b,c
Comorbidities
Type 2 diabetes mellitus, n (%) 0 22 (48.9) 30 (23.8) e
Cardiovascular disease, n (%) 0 18 (40) 68 (54)
Chronic liver disease, n (%) 0 0 1 (0.8)
Chronic lung disease, n (%) 0 0 18 (14.3)
Chronic kidney disease, n (%) 0 19 (42.2) 22 (17.5) d
Chronic neurological disease n (%), 0 0 29 (23)
Cancer, n (%) 0 17 (37.8) 16 (12.7) e
Charlson Index No comorbidity, n (%) NA 10 (22.2) 83 (65.9) e,*
Low comorbidity, n (%) 18 (40.0) 29 (23.0)
High comorbidity, n (%) 17 (37.8) 14 (11.1)
McCabe Index RFD, n (%) NA 10 (22.2) 7 (5.6) e, *
UFD, n (%) 19 (42.2) 31 (24.6)
NFD, n (%) 16 (35.6) 88 (69.8)
Medications
ACEIs, n (%) NA 14 (31.1) 24 (27.0)
ARAs, n (%) NA 12 (26.7) 21 (16.7)
Oral antidiabetics, n (%) NA 19 (42.2) 37 (29.4)
Insulin, n (%) NA 9 (20.0) 28 (22.2)
Statins, n (%) NA 16 (35.6) 44 (34.9)

ap < 0.01, b p < 0.001, with respect to healthy subjects; c p < 0.05, d p < 0.01, e p < 0.001 with respect to COVID-19 negative patients. *: Global P-value including the three categories of each index. Statistical analyses were performed by the Student’s t-test (quantitative) or the χ-square test (qualitative). Results are given as medians and 95% CI, or as numbers and percentages. ACEIs: Angiotensin-converting enzyme inhibitors; ARAs, Angiotensin II receptor antagonists; NFD: Non-fatal disease; RFD: Rapidly fatal disease. UFD: Ultimately fatal disease.